[Maintenance treatment by anti-tumor necrosis factor monoclonal antibody in Crohn's disease--long-term effects and safety].
Matsui
Toshiyuki
T
Department of Gastroenterology, Fukuoka University Chikushi Hospital.
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy* / Q000534:rehabilitation; D004334:Drug Administration Schedule; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000069285:Infliximab; D012074:Remission Induction; D012449:Safety; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab